GB0821994D0 - In viva imaging method - Google Patents

In viva imaging method

Info

Publication number
GB0821994D0
GB0821994D0 GBGB0821994.1A GB0821994A GB0821994D0 GB 0821994 D0 GB0821994 D0 GB 0821994D0 GB 0821994 A GB0821994 A GB 0821994A GB 0821994 D0 GB0821994 D0 GB 0821994D0
Authority
GB
United Kingdom
Prior art keywords
imaging method
viva imaging
viva
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0821994.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Priority to GBGB0821994.1A priority Critical patent/GB0821994D0/en
Publication of GB0821994D0 publication Critical patent/GB0821994D0/en
Priority to CN2009801562662A priority patent/CN102300589A/zh
Priority to US13/132,109 priority patent/US20110236307A1/en
Priority to JP2011538991A priority patent/JP2012510499A/ja
Priority to PCT/EP2009/066120 priority patent/WO2010063701A2/en
Priority to EP09768015A priority patent/EP2389200A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB0821994.1A 2008-12-02 2008-12-02 In viva imaging method Ceased GB0821994D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB0821994.1A GB0821994D0 (en) 2008-12-02 2008-12-02 In viva imaging method
CN2009801562662A CN102300589A (zh) 2008-12-02 2009-12-01 用于帕金森氏病症的体内成像方法
US13/132,109 US20110236307A1 (en) 2008-12-02 2009-12-01 In vivo imaging method
JP2011538991A JP2012510499A (ja) 2008-12-02 2009-12-01 生体内イメージング法
PCT/EP2009/066120 WO2010063701A2 (en) 2008-12-02 2009-12-01 In vivo imaging method
EP09768015A EP2389200A2 (en) 2008-12-02 2009-12-01 In vivo imaging method for parkinson's disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0821994.1A GB0821994D0 (en) 2008-12-02 2008-12-02 In viva imaging method

Publications (1)

Publication Number Publication Date
GB0821994D0 true GB0821994D0 (en) 2009-01-07

Family

ID=40262535

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0821994.1A Ceased GB0821994D0 (en) 2008-12-02 2008-12-02 In viva imaging method

Country Status (6)

Country Link
US (1) US20110236307A1 (OSRAM)
EP (1) EP2389200A2 (OSRAM)
JP (1) JP2012510499A (OSRAM)
CN (1) CN102300589A (OSRAM)
GB (1) GB0821994D0 (OSRAM)
WO (1) WO2010063701A2 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101297815B1 (ko) * 2010-11-18 2013-09-03 충남대학교산학협력단 폴리감마글루탐산과 광학영상다이의 복합체를 함유하는 센티넬 림프노드 감지용 광학영상 프로브
KR102563040B1 (ko) 2014-06-25 2023-08-02 뉴카나 피엘씨 젬시타빈 전구 약물
KR20240036709A (ko) 2016-03-11 2024-03-20 에이씨 이뮨 에스에이 진단 및 치료를 위한 바이사이클릭 화합물
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
EP3562487B1 (en) 2016-12-29 2023-11-29 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
MX2021011775A (es) 2017-04-26 2023-01-10 Basilea Pharm Int Ag Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos.
CN112105393A (zh) * 2018-05-16 2020-12-18 爱默蕾大学 苯乙烯基苯并噻唑衍生物及在成像中的用途
ES2988770T3 (es) 2018-06-08 2024-11-21 Ac Immune Sa Nuevos compuestos para diagnóstico
WO2020056064A1 (en) 2018-09-11 2020-03-19 Stanley Satz Tumor targeted radionuclide therapy and molecular imaging of her2+ cancers and other neoplasms, and precision medicine.
CN114269383A (zh) 2019-01-08 2022-04-01 菲斯生物制药公司 金属酶抑制剂化合物
CA3175602A1 (en) 2020-05-07 2021-11-11 Jerome Molette Novel compounds for diagnosis
WO2023084000A1 (en) 2021-11-10 2023-05-19 Ac Immune Sa 4h-imidazo[1,5-b]pyrazole derivatives for diagnosis
EP4430044A1 (en) 2021-11-10 2024-09-18 AC Immune SA Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis
US20250034149A1 (en) 2021-11-10 2025-01-30 Ac Immune Sa Dihydropyrrolo[3,4c]-pyrazole derivatives and their use in diagnosis
EP4634191A1 (en) 2022-12-16 2025-10-22 AC Immune SA Novel compounds for diagnosis
JP2026500311A (ja) 2022-12-16 2026-01-06 エーシー・イミューン・エス・アー 診断のための新規化合物
EP4733299A1 (en) 2023-05-22 2026-04-29 Shenzhen Braegen Pharmaceutical Co., Ltd. Sulfur-containing fused ring compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
WO2025037013A1 (en) 2023-08-16 2025-02-20 Ac Immune Sa Diagnostic compounds that bind to alpha-synuclein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
US6379650B1 (en) * 2001-03-19 2002-04-30 Wesley Scott Ashton Technetium 99m-N2S2-congo red complexes utilizing diamide dithiolate ligand systems for radioimaging
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US8329142B2 (en) * 2003-05-29 2012-12-11 Pettegrew Jay W Compounds, compositions and methods for medical imaging of Parkinson's disease
WO2007011834A2 (en) * 2005-07-15 2007-01-25 The Regents Of The University Of California Compounds and method for the diagnosis and treatment of amyloid associated diseases
AU2006320556A1 (en) * 2005-12-01 2007-06-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Isotopically-labeled benzothiazole compounds as imaging agents for amyloidogenic proteins
WO2008060364A2 (en) * 2006-10-02 2008-05-22 Ac Immune S.A Humani zed antibody against amyloid beta
WO2008030973A2 (en) * 2006-09-06 2008-03-13 The Board Of Regents Of The University Of Texas System Methods and compositions for the detection of protein folding disorders
WO2008121407A1 (en) * 2007-03-30 2008-10-09 The Regents Of The University Of California In vivo imaging of sulfotransferases

Also Published As

Publication number Publication date
JP2012510499A (ja) 2012-05-10
EP2389200A2 (en) 2011-11-30
WO2010063701A2 (en) 2010-06-10
CN102300589A (zh) 2011-12-28
US20110236307A1 (en) 2011-09-29
WO2010063701A3 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
GB0820927D0 (en) Method
AP2015008431A0 (en) Improvements in feedwells
GB0818093D0 (en) Method
GB0803107D0 (en) Method
GB0822836D0 (en) Method
GB0810418D0 (en) Method
GB0804981D0 (en) Method
GB0804690D0 (en) Method
GB0807409D0 (en) Method
GB0813599D0 (en) Method
GB0815428D0 (en) Method
GB0821884D0 (en) Desalination method
GB0807410D0 (en) Method
ZA201101329B (en) Recarburisation method
GB0906449D0 (en) Improvements in imaging
GB0818738D0 (en) Imaging neuroflammation
GB0809404D0 (en) Method
ZA201008728B (en) Method
GB0818151D0 (en) Imaging techniques
GB0813494D0 (en) Method
GB0805862D0 (en) Method
GB0922037D0 (en) Method
GB0812102D0 (en) Method
GB0806186D0 (en) Method
GB0811166D0 (en) Method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)